؉ cells of the proliferating compartment during MDS evolution (RA/RARS 0.35%, RAEB(t) 1.44% and sAML 11.98% of all S-phase cells). These CD34
Introduction
In myelodysplastic syndromes (MDS) the initial DNA-altering event probably occurs at the level of the pluripotent stem cell. This early event may cause a change in the cell cycle control mechanism that leads to a growth advantage of this particular clone over their normal counterparts. This clonal expansion causes the frequently found monoclonal hematopoiesis of the nonlymphoid cells in MDS. [1] [2] [3] [4] [5] During this process of high proliferative activity secondary events (DNA damaging events or DNA repair mechanism failures) induce a cytogenetically marked subclone, like the frequently found 5q−, monosomy 7, trisomy 8 clones in MDS. 6 This subclone or the following subclones [7] [8] [9] are characterized by even more complex cytogenetic abnormalities and are recognised by their immaturity as blasts and/or as abnormally localised immature precursors (ALIPs). [10] [11] [12] Eventually these subclones may cause the evol- ution from RAEB(t) to acute myeloid leukemia (AML) by progressive dedifferentiation and eventually losing their genedirected programmed cell death (PCD) or apoptosis. 13, 14 Over several years more evidence has been found that the high labeling index (LI) in MDS is abrogated by a high apoptotic cell death, 9, [14] [15] [16] which explains the hypercellular BM with peripheral cytopenias. This increased apoptosis in MDS is visualized by different techniques like high/low molecular weight DNA extraction by electrophoresis, in situ end labeling of DNA (ISEL), in situ terminal deoxynucleotidyl transferase assay (TUNEL) and the Annexin-V assay by different research groups. [17] [18] [19] [20] [21] When RA/RARS develops to RAEB(t) overall apoptosis is high. It slows down during the development of secondary AML (sAML after previous MDS) because of the appearance of a progressive number of ISEL-negative, immature myeloblasts. On the other hand, the high myeloid LI decreases with slowing down of cell cycle times of myeloblasts when evolution occurs to RAEBt and sAML. 9, 13, 15, 22 It is still not proven whether the high proliferation rate (mean overall myeloid LI of 25 to 30%) is a compensatory mechanism for the high apoptosis rate in myelodysplasia. 9, 23 However, first results of treating MDS patients with pentoxifylline and ciprofloxacin support this hypothesis: suppression of PCD (by turning down transcription of TNF␣) was followed by a decrease in overall myeloid LI. 24 Very little is known regarding the specific proliferative characteristics of CD34 + cells in particular in MDS. By flow cytometry, a sufficient number of stem cells after selection procedures can usually be obtained, but determining an accurate LI from aspirated and separated cells is frequently proven to be unreliable. 25, 26 The best way of determining the accurate LI is obtaining BM biopsies after in vivo labeling of S-phase cells. 13 Fortunately, we have been able to develop an in vivo method to identify CD34 + cells and to simultaneously examine their proliferative characteristics in BM biopsies. Therefore, we conducted this study to achieve a better understanding of their cycling properties during MDS evolution and to study the process of a possible growth advantage of the clone within the CD34 + compartment, as more immature myeloblasts occur during MDS progression to sAML.
Materials and methods

Patients
Thirty-three MDS patients (21 males and 12 females, mean (± s.d.) age 65.8 (±13.8) years were studied for the proliferative characteristics of CD34 + cells. All MDS patients (FAB classification: 19 RA, 5 RARS, 7 RAEB and 2 RAEBt), together with five sAML patients (four males and one female, mean age 52.8 (±10.4) years and five 'normals' (lymphoma patients with uninvolved BM, four males and one female, mean age 56.8 (±22.7) years who served as controls were eligible for study after informed consent was obtained. None of the patients had received any therapy except supportive care for at least 2 weeks prior to the 1-h infusion of one of the thymidine analogues iodo-or bromodeoxyuridine (IUdR/BrdU) at 100 mg/m 2 i.v., using a constant rate infusion pump. Each infusion was immediately followed by a BM aspirate and biopsy, which were handled on ice. The infusion protocols were reviewed and approved by the Investigative Review Board (IRB) of the Rush Presbyterian St Luke's Medical Centre, National Cancer Institute (NCI) and the Food and Drug Administration (FDA). The drugs were supplied by NCI. See Table 1 for detailed individual characteristics of all patients and controls.
Single-labeling immunohistochemistry to measure overall myeloid LI
The BM biopsies were labeled by 3D9 (Bioscience, Bethlehem, PA, USA) antibodies against incorporated IUdR/BrdU to detect S-phase cells by showing a brown punctation overlying their nuclei. After counterstaining and taking myeloid morphology into account an overall myeloid labeling index (LI) could be determined. This procedure has been described before in full detail 27 and was also followed for the sAML patients and controls.
Double-labeling immunohistochemistry CD34/BrdU to measure CD34 cells in S-phase or not
After fixation and decalcification of the BM biopsies embedding in paraffin was performed. Sections of approximately 6 m were placed on positively charged Superfrost Plus slides, air-dried and used for immunohistochemistry at room temperature. After deparaffinization by running through 100% xylene and graded ethanols, rehydration in double distilled water (ddH 2 O) was followed by incubation in freshly prepared 3% H 2 O 2 for 30 min to block endogenous peroxidase. After rinsing thoroughly in ddH 2 This procedure was started by applying 1 mg/ml nuclease free pronase (Calbiochem, La Jolla, CA, USA) for 45-min incubation followed by three washes in 0.15 m PBS. 4 N HCl treatment for 20 min was done to permeabilize cell and nuclear membrane, which was followed by dip rinsing in ddH 2 antibody ABC (avidinbiotin/peroxidase complexes, Vectastain Elite Kit) was also incubated for 30 min and followed by three washes in 0.5 m PBST. The brown color reaction was developed in the nucleus with 50 mg DAB (3,3Ј-diaminobenzidine tetrahydrochloride, Sigma) in 200 ml 0.05 m Tris buffer, pH 7.5, together with 12-14 l 30% H 2 O 2 for 4 to 10 min, followed by three rinses in ddH 2 O. Postfixation for the BCIP blue color was needed and performed with 2% glutaraldehyde at 4°C for 20 min. Dehydration of these paraffin sections was done by graded ethanols. After going through 100% xylene three times 30 s, the slides were mounted with xylene-based mounting solution (Permount) using 2 m thick glass coverslips. No counterstain was used in this double-labeling procedure.
Single-labeling immunohistochemistry to measure the percentage of absolute CD34 + cells of all total myeloid cells
The same procedure after deparaffinization was followed as the first day of the double-labeling procedure but we used DAB/ABC-kit to detect the CD34 + labeled cells (brown cytoplasm and cell membrane) and counterstained the biopsy slides with hematoxylin to differentiate CD34 + cells from the other myeloid cells. No postfixation treatment was needed for these slides.
Morpho-immunohistochemical evaluation of BM biopsies: detection and scoring of CD34 + cells and/or S-phase cells within the myeloid compartment
At least 2000 positively labeled S-phase cells were counted from five or more areas of the single-labeled biopsy for determination of the LI (%). Furthermore, 2000 S-phase labeled myeloid cells were counted by searching for CD34 + fields (aggregates or single cells) in the double-labeling method, whereas to 2000 myeloid cells were counted by searching for CD34
+ cells in the single-labeling method. Aggregates of three or more CD34
+ cells were seen and scored as a number of single cells. Erythroid and megakaryocytic cells were excluded by morphology. The first slides were scored by an experienced team after visualizing the slides on screen and discussing which cells would be scored as CD34
+ positive (clearly stained) and which ones not (hardly or not stained). After this procedure the total evaluation of the slides was done twice (on different days) by the same person, who is an experienced hematomorphologist. The following cells were counted and expressed as a percentage of one of the three different compartments (see Figure 1 
Autoradiography for determining T s (duration of Sphase or DNA doubling time) and calculation of T c
The bone marrow aspirate samples were double-labeled in vitro with tritiated thymidine for the calculation of the dur-
Figure 1
Overall myeloid compartment contains CD34 + and CD34 − compartments, both contain a proliferating fraction, taken together as S-phase compartment or LI of overall myeloid compartment.
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+ cells during the evolution of MDS to AML LFR Span et al 1688 ation of S-phase (T s ) by our previously described method. 13 With the use of T s and LI the total cell cycling time T c of all myeloid cells can be calculated using the formula described by Wimber and Quastler: 28 T c = T s × GF/LI. GF is the growth fraction or the percentage of cells in cycle, which was assumed to be 100%. T s and T c are both expressed in hours (h) in Table 1 .
Statistical analysis (Table 2)
After analyzing the distribution of the different continuous variables in the various subgroups only LI, T s and T c showed a Gaussian distribution in all the subgroups. Therefore, a distribution-free Wilcoxon Mann-Whitney test was used to determine statistical significant differences (P Ͻ 0.05) between these skewed-distributed subgroups. Also the use of median values (with 25-75% interval) is statistically seen more correct than the mean values to describe these parameters when skewed distributions are involved. Pearson rank correlation tests were used to analyze statistically significant correlations (P Ͻ 0.05) between various sets of two different variables within these subgroups.
Results
After applying the double-labeling immunohistochemistry technique, CD34
+ cells showed a blue colored cytoplasm and cell membrane with variable intensity while the S-phase cells showed brown staining overlying the nucleus (see Figure 2) . CD34
+ cells in S-phase are therefore double-labeled. Aspecifically blue stained blood vessel endothelium and collagen by QBend/10 was not taken into account but served as positive internal control. The majority of cells were non-stained CD34
− cells not in S-phase. Sometimes CD34 + aggregates could be found in which all the cells were in S-phase, especially in sAML and the more advanced stages of MDS (see Figure 5 ). The mean values (± s.e.m.) of the different proliferative parameters of all the groups are shown in Table 2 and Figures 3 and 4 . Statistical differences between the various subgroups and the level of significance are also expressed in Table 2 in combination with the medians (with 25-75% interval) of only the skewed-distributed parameters. Table 2 Proliferative characteristics of the CD34, S-phase and overall myeloid compartments in controls, MDS subgroups and sAML
Variable
Controls n = 5 RA/RARS n = 24 RAEB(t) n = 9 sAML n = 5 
Labeling index of myeloid cells and CD34 + cells during MDS evolution
A statistically non-significant decrease occurred in the mean overall myeloid LI: RA/RARS 25.8%, RAEB(t) 24.6% and sAML 21.5% (see Table 2 and Figure 3 ). The controls/lymphoma patients with uninvolved BM had an unexpectedly and unexplained high LI. Next we looked at the size of the CD34 + compartment and the LI of CD34 + cells. A significant increase in the mean percentage of CD34 + cells of all myeloid cells was found with the progression from RA to sAML. The percentages CD34 + cells were 1.67% in RA/RARS, 8.68% in RAEB(t) and 23.83% in sAML, much higher as compared to 0.22% of the controls (see Figure 3) . On the other hand no significant differences were found in the LI of CD34 + cells during MDS evolution. The mean percentage of proliferating CD34
+ cells within the CD34 compartment was 9.60% in RA/RARS, 6.29% in RAEB(t) and 9.33% in sAML. However, when the proliferating compartment of CD34 + cells as a fraction of all myeloid cells (CD34S/M) was analyzed a significant exponential increase was found during MDS evolution: 0.189% in RA/RARS, 0.429% in RAEB(t) and 3.304% in sAML (see Figure 3 ). An exponential increase of proliferating CD34 + cells as a fraction of all myeloid proliferating cells (CD34S/S) was also seen with progression of myelodysplasia to sAML: 0.35% in RA/RARS, 1.44% in RAEB(t) and 11.98% in sAML (see Figure 3) . Sometimes we observed CD34
+ aggregates in which all the cells were in S-phase, especially in patients with a high CD34 expression (see Figure 5 ).
These data suggest that the CD34 + compartment increases as MDS progresses to sAML. Within this compartment the percentage proliferating CD34
+ cells remains the same (LICD34). The absolute number of proliferating CD34 + cells (CD34S/M) increases therefore, whereas a decreasing trend occurs in the size of the overall myeloid proliferating compartment as MDS evolves to sAML (LI). This means that within this decreasing proliferating overall myeloid compartment the fraction of proliferating CD34 + cells (CD34S/S) increases at the expense of the proliferating CD34 − fraction during MDS evolution to sAML. The aforementioned changes in the different compartments are shown together in Figures 6a and b .
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Figure 2
Double-labeling immunohistochemistry CD34/BrdU in MDS bone marrow biopsy: CD34 + cells show blue cytoplasm and cell membrane whereas S-phase cells show a brown nuclear staining. CD34
+ cells in S-phase have both features.
Duration of cell cycle phases
As MDS evolves to sAML the mean total cell cycling time increased progressively, although it just missed statistical significance, whereas no change occurred in the mean duration of S-phase. The mean T c and T s in the different subgroups are respectively 39.8 and 9.28 h for RA/RARS, 45.2 and 10.5 h for RAEB(t) and 65.8 and 11.0 for sAML (see Table 2 and Figure 4 ).
Correlations between various proliferative characteristics within the different subgroups
Within the RA/RARS and RAEB(t) subgroups a strong significant correlation was found between T c and T s , respectively r = 0.84 (P Ͻ 0.0004) and r = 0.99 (P Ͻ 0.0004), which was not found within the sAML group. Within the RA/RARS an increase in the CD34 + fraction of the total myeloid LI leads to a longer T s and to a longer overall T c because the percentage proliferating CD34 + cells of all myeloid S-phase cells (CD34S/S) was significantly positive correlated with T c , T s and CD34S/M (respectively r = 0.59 (P Ͻ 0.04), r = 0.72 (P Ͻ 0.008) and r = 0.59 (P Ͻ 0.005). Also CD34S/M was significantly correlated with T c and T s , respectively r = 0.74 (P Ͻ 0.006) and r = 0.70 (P Ͻ 0.01). The size of the CD34 + compartment depends on the percentage of proliferating CD34
+ cells of all myeloid cells: CD34 was significantly correlated with CD34S/M (r = 0.64, P Ͻ 0.002). This means that within the CD34 + compartment the balance between cell proliferation or cycling is favored over apoptosis.
Within the RAEB(t) group and the controls we did not find any of the aforementioned correlations. Regarding the sAML group, similar characteristics were found as in the RA/RARS group: a higher CD34 + fraction within the overall myeloid LI leads to a longer overall Tc and an increment in the percentage of proliferating CD34
+ cells of all myeloid cells because the percentage of proliferating CD34 + cells of all S-phase cells (CD34S/S) was positively correlated with T c (r = 0.99, P Ͻ 0.08) and CD34S/M (r = 0.94, P Ͻ 0.02). Furthermore, the percentage CD34
+ cells of all myeloid cells (CD34) was positively correlated with CD34S/S and CD34S/M, respectively r = 0.86 (P Ͻ 0.06) and r = 0.83 (P Ͻ 0.08). Only in sAML a positive correlation was found between LICD34 and CD34S/M (r = 0.90, P Ͻ 0.04). This means that in sAML the balance between CD34 cell proliferation or cycling and apoptosis is even more favored for proliferation than is the case in RA/RARS.
Within the controls a strong negative correlation was found between LI and CD34: r = −0.94, P Ͻ 0.06, which can be explained by slower cycling properties of CD34 + cells as compared with CD34
− cells, which is normal physiology.
Discussion
The aim of this study was to get a better insight into the biology of CD34 + cells in relation to the overall myeloid population during the evolution of MDS. Therefore we investigated the evolutionary pattern of proliferation of myeloid cells in general and CD34 + cells in particular by means of immunohistochemistry double-labeling on BM biopsies. In patients with a low CD34 expression the CD34 parameters are a little overinterpreted because of searching for positive fields for CD34 expression. This is not the case in patients with a high CD34 expression because of the fact that every field could be scored. Despite some overinterpretation, our values of CD34 (%) are within the same range for the different FAB classifications as a similar study of Soligo et al 29 using a different method for scoring single-label CD34 immunohistochemistry in BM biopsies of MDS patients.
During MDS progression we observed a significant increment in the percentage of CD34
+ cells of all myeloid cells (CD34), which means that the enlargement of the CD34
+
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Figure 3
Proliferative characteristic of overall myeloid and CD34 + cells during MDS evolution.
compartment follows a concomitant increase in the percentage of BM blasts by FAB classification. Furthermore, as the overall myeloid LI shows a decreasing tendency from MDS transition to sAML, the percentage proliferating CD34 + cells of all myeloid cells (CD34S/M) increases exponentially with no significant change in the LI of CD34
+ cells. This means that the percentage S-phase cells in the increasing CD34 + compartment remains the same but the absolute number of proliferating CD34
+ cells in the CD34 + compartment increases and consequently the absolute number of proliferating CD34 + cells of all myeloid cells. This can be (partially) explained by an exponential increment in the percentage of proliferating
Expansion of CD34
+ cells during the evolution of MDS to AML LFR Span et al 1691
Figure 4
Mean total cell cycling time (T c in h). ND, not determined. 
CD34
+ cells of all myeloid cells in S-phase (CD34S/S). Furthermore, a decreasing number of myeloid cells in S-phase concurrently with an increase in T c and no change in T s during MDS evolution to sAML can be explained by the slower proliferation of the enlarged proliferating CD34 + compartment. Immature CD34 + blasts must cycle slower than their CD34 − counterparts, otherwise a fast CD34 + overgrowth within the BM would occur in every case of MDS, unless apoptosis or a rapid transit time to the CD34 − compartment would prevent this overgrowth. From previous proliferation studies we already know that during the evolution within MDS and to sAML the overall myeloid LI decreases as T c prolongs, 9, 26 but it still has to be proven if (a substantial number of) these increased CD34
+ clonogenic blasts with a longer duration of G0/G1-phase cause this phenomenon. Above all, the phenomenon of 'signal antonymy' (dying S-phase cells) in MDS was not taken into account and this characteristic feature of MDS has to be investigated also for its implications for measuring overall T s and consequently T c .
Myelodysplasia is primarily characterised by a phase of monoclonality before a (rapid) expansion of leukemic blasts occur. Mehrotra et al 4 showed in AML that the frequency of cytogenetically aberrant stem cells (CD34 + lin − ) is uncoupled from compartment size, which means that additional mutation(s) and maturation to the blast subpopulation is needed before compartmental expansion can occur. Also in myelodysplasia these characteristics can be found. 30, 31 Furthermore, it was also found by interphase FISH analysis that the percentage of cytogenetically aberrant cells in the CD34 − compartment was higher than in the CD34 + compartment in good prognosis MDS, whereas this percentage of aberrant cells was almost the same in both compartments in poor prognosis MDS. 30 Dynamic processes of clonal expansion and suppression of normal hematopoiesis and the balance between them are involved in these phenomena. These additional mutations may lead to apparent (and eventually malignant) clonal expansion by several mechanisms: enhanced dedifferentiation or differentiation arrest, increased autonomic proliferation, turning down of apoptosis and eventually decreasing cell cycling times of clonogenic blasts.
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+ cells during the evolution of MDS to AML LFR Span et al The first three mechanisms are clearly incorporated in the FAB classification: the progression of blasts. Enhanced dedifferentiation of MDS CD34
+ cells was also found in in vitro cultures upon growth factors. [32] [33] [34] No clear reports can be found investigating the increased autonomic proliferation in MDS. In RAEB(t) and sAML we previously showed less overall apoptosis, especially in blasts, by using ISEL on BM biopsies. 14 This phenomenon was also recently reported by Bouscary et al 35 showing a lower FAS expression on CD34 + cells of patients with advanced stages of MDS and sAML when compared with early MDS stages, which was also associated with less PCD by the TUNEL technique. In this study we found a strong positive correlation between LICD34 and CD34S/M only in sAML (r = 0.90, P Ͻ 0.04), probably because apoptosis was found to be completely negative in this clonogenic blast population.
14 Evidence for increased proliferation with slower cell cycling times of CD34 + cells during MDS progression is also reported in this article. The mechanism of eventually decreasing total cell cycling times is seen in the clonogenic blast subpopulation of ALIP-positive RAEB(t) patients with a very fast evolution to sAML. 11, 13 The typical profile of exponential proliferation of CD34 + cells during MDS evolution may be explained by a progressive autonomous proliferation in the CD34 + compartment. Some evidence seen in our biopsies for a possible role of paracrineinduced 'signal synchronisation' in CD34 + aggregates, in which all the CD34 + cells were in S-phase, could be used as a morphological substrate for this autonomic proliferation. Increasing evidence for autocrine and/or paracrine mechanisms for the explanation of the autonomous growth of (and anti-apoptotic effects in) AML blasts is found in the literature today, 36, 37 but no studies in MDS are performed or reported as yet.
Different groups have already shown that the absolute percentage of CD34 + cells/blasts (CD34%) increases during the evolution of MDS. 38, 39 The MDS CD34 + cells show clearly promoted proliferative capacity (high cluster/colony ratio in semi-solid medium) with strongly impaired differentiation upon growth factors in in vitro cultures. [32] [33] [34] TNF␣ is one of the cytokines which may have a dual role in this process: stimulation of proliferation of presumably early progenitor cells and induction of apoptosis in their more mature progeny. 9, 14, 20, 40, 41 29, 32 The number of CD34 + aggregates in MDS biopsies are significantly positively correlated with the percentage of BM blasts and ALIPs. 45 A significantly higher frequency of CD34 expression is also found in sAML (or therapyrelated AML) when compared with de novo AML. 46 We showed in the present study a continuous process of increasing CD34 expression during the evolution of myelodysplasia to sAML caused by an increasing fraction of CD34 + cells within the total S-phase population. CD34-positivity in BM and the presence of CD34
+ cells in circulation in MDS are both correlated with poor overall prognosis and with leukemic transformation.
12, 29, 32, 47, 48 Within AML after MDS the prognostic relevance of CD34 expression has not been demonstrated yet, because no studies on this selected subgroup within AML have been performed. In this study we found a higher CD34 expression in AML after previous MDS as compared with the MDS subgroups, which is the first evidence in literature of a prognostic meaning of CD34 expression in AML-MDS. This poor prognostic meaning of increasing CD34
+ aggregates, as well as increasing CD34 + circulating cells in MDS can probably be explained by 'signal synchronisation'. This means that growth signalling in these clonogenic blast cell aggregates occurs in a paracrine fashion causing these cells to go into S-phase at the same time. This phenomenon is possibly responsible for autonomic growth by overruling the need for stromal interactions for proliferation (see Figure 5 ). These speculations fit perfectly in the following model: when no or less stromal interaction for growth purposes is needed, less activation of the cytokine-dependent ␤1-integrins very late antigen (VLA)-4 and VLA-5 on the CD34 + cells can be assumed, which leads to a lower BM fibronectin adhesion and a higher chance of circulating CD34 + cells. [49] [50] [51] Above all, recently a lower expression of the cell adhesion molecule L-selectin was found in this primitive CD34 + cell population of MDS patients compared to normals. 52 From a prognostic perspective, it may therefore be very important to apply this double-labeling immunohistochemistry to determine how many CD34 + cells and CD34 + aggregates can be found in the BM biopsies and especially how many of them are in S-phase.
S-phase specific agents like cytosine arabinoside (Ara-C) are considered to be most effective in MDS. If chronic cytoreductive therapy (like low-dose Ara-C) is effective enough to kill (because T c increases with no change in T s ) the aberrant CD34 + stem cell clone(s) will be uncertain. New therapeutic options in the growing population of MDS patients have to be developed. The combination of cytoreductive therapy and biological therapy directed to suppression of proliferation of the aberrant CD34 + clone(s) and suppression of apoptosis of more differentiated BM cells may restore normal polyclonal hematopoiesis in MDS patients.
In summary, as MDS evolves from low-risk to high-risk groups and eventually sAML we observed an increase in absolute CD34
+ cells, as well as an increase in absolute CD34 + cells in S-phase in BM biopsies, which contributes to the observed decrease in overall myeloid LI. We believe that this phenomenon is the result of clonal expansion of genetically altered blast cells with less or no apoptosis and with slower proliferation rates than their more mature counterparts in a different microenvironment of cytokines and probably changed stromal interactions. The immunohistochemical double-labeling technique we described can be used to follow MDS evolution and probably determine prognosis and leukemic transformation with greater accuracy than before and irrespective of their FAB subtype, like Oriani et al 48 have shown for single-labeling CD34 immunostaining. The different biological processes which lead to changes in size and proliferative capacity of the CD34 + and CD34 − compartments within MDS in evolution have been discussed and are pathophysiologically expressed in Figure 7 .
